参附注射液辅助治疗对冠心病慢性心力衰竭患者生活质量及生存情况的影响  

Impact of Shenfu Injection(参附注射液) Adjunctive Therapy on Quality of Life and Survival Condition of Patients with Coronary Heart Disease with Chronic Heart Failure

作　　者：姚魁武[1] 陈孟倩 刘甜甜[2] 刘张静[1] 王欣[3] 郭宇[4] 姜敏[5] 王占荣[5] 冯兴中[5] 张良登[5] 

机构地区：[1]中国中医科学院广安门医院,北京市西城区北线阁5号100053 [2]首都医科大学 [3]中国中医科学院望京医院 [4]北京中医药大学 [5]首都医科大学附属北京世纪坛医院

出　　处：《中医杂志》2016年第24期2117-2120,共4页Journal of Traditional Chinese Medicine

基　　金：首都医学发展科研基金北京医学卫生科技联合攻关项目(SF-2007-I-04)

摘　　要：目的观察参附注射液辅助常规西药治疗冠心病慢性心力衰竭的临床疗效。方法将102例冠心病慢性心力衰竭心肾阳虚证患者随机分为治疗组与对照组各51例。对照组予西医常规治疗,治疗组予参附注射液40 ml/d静脉滴注辅助西医常规治疗,分别在治疗前及治疗2周应用明尼苏达心力衰竭生活质量调查表(LHFQ)进行生活质量评价,并于治疗前、治疗1周与2周分别进行中医证候评分,以电话或门诊方式随访进行生存情况分析。结果治疗组治疗2周后中医证候疗效显效19例,有效22例,无效6例,恶化4例,总有效率80.39%;对照组分别为13例、21例、10例、7例及66.67%,两组比较治疗组优于对照组(P<0.05)。两组治疗2周LHFQ总分均较本组治疗前下降(P<0.05)。两组治疗1周、2周中医证候总积分均较本组治疗前下降(P<0.05),治疗2周治疗组中医证候总积分均低于同时间点对照组(P<0.05)。治疗组生存率为96.1%高于对照组的82.4%(P<0.05)。结论参附注射液辅助西药常规治疗冠心病慢性心力衰竭可提高临床疗效及生存时间,改善临床症状及生活质量。Objective To examine the clinical effect of Shenfu Injection assisting routine western drug to treat coronary heart disease with chronic heart failure. Methods Totally 102 cases of coronary heart disease with chronic heart failure with syndrome of Yang deficiency of heart and kidney were randomized into a treatment group （51 cases） and a control group （51 cases）. The control group was given western medicine routine therapy. The treatment group was given Shenfu Injection 40 ml/d intravenous drip to assist western medicine routine therapy. The Minnesota Living with Heart Failure questionnaire （MLHFQ） was applied to evaluate quality of life before and 2 weeks after treatment. Chinese medicine syndrome score was rated before, and 1 week and 2 weeks ＇after treatment. Survival condition analysis was made by telephone or during outpatient follow-up Results After 2 weeks of treatment, as for Chinese reedicine syndrome effect, there were 19 cases markedly improved, 22 improved, 6 invalid, and 4 getting worse in the treatment group, with the total effective rate of 80.39%. In the control group, there were 13 cases markedly improved, 21 improved, 10 invalid, and 7 getting worse, with the total effective rate of 66.67%. The treatment group was superior to the control group （ P 〈 0.05 ）. The total score of MLHFQ in both groups decreased 2 weeks after treatment （P 〈 0. 05 ）. The total score of Chinese medicine syndrome in both groups decreased one and 2 weeks after treatment （P 〈 0. 05）. The total score of Chinese medicine syndrome in the treatment group 2 weeks after treatment was lower than that in the control group at the same time point （P 〈 0. 05 ）. The survival rate of the treatment group was 96. 1%, higher than 82. 4% in the control group （ P 〈 0.05 ）. Conclusion Shenfu Injection assisting western drug routine therapy might enhance the clinical effect, extend survival time, relieve clinical symptoms, and improve quality of life in the treatment of coronary heart disease with c

关 键 词：冠心病 慢性心力衰竭 参附注射液 生活质量 生存分析 

分 类 号：R541.4[医药卫生—心血管疾病] R541.6[医药卫生—内科学]